Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allen Chung

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Biorxiv : the Preprint Server for Biology|June 6, 2025
Comprehensive Multimodal Profiling of Atherosclerosis Reveals Bhlhe40 as a Potential Regulator of Vascular Smooth Muscle Cell Phenotypic ModulationChinyere O Ibikunle, Chenyi Xue, Eunyoung Kim, et al.
Cell Reports|July 16, 2020
Macrophage Exosomes Resolve Atherosclerosis by Regulating Hematopoiesis and Inflammation via MicroRNA CargoLaura Bouchareychas, Phat Duong, Sergio Covarrubias, et al.
Infection and Drug Resistance|January 13, 2025
Comparison of Clinical Characteristics and Mortality Outcome in Critical COVID-19 Patients Infected with Alpha and Omicron VariantsHsin-I Cheng, Ko-Wei Chang, Bing-Chen Wu, et al.
Thoracic Cancer|October 16, 2019
Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression controlShih-Hao Huang, Allen Chung-Cheng Huang, Chin-Chou Wang, et al.
Medrxiv : the Preprint Server for Health Sciences|July 28, 2023
High-Dimensional Single-Cell Multimodal Landscape of Human Carotid AtherosclerosisAlexander C Bashore, Hanying Yan, Chenyi Xue, et al.
Frontiers in Oncology|October 19, 2023
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitorsPing-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, et al.
Therapeutic Advances in Medical Oncology|August 11, 2021
First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancerAllen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, et al.
Cancers|January 21, 2022
Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor MutationChih-Hsi Scott Kuo, Tzu-Hsuan Chiu, Pi-Hung Tung, et al.
Scientific Reports|March 16, 2022
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasisTzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, et al.
Targeted Oncology|February 22, 2023
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in TaiwanPing-Chih Hsu, Suey-Haur Lee, Li-Chung Chiu, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Biorxiv : the Preprint Server for Biology|June 6, 2025
Comprehensive Multimodal Profiling of Atherosclerosis Reveals Bhlhe40 as a Potential Regulator of Vascular Smooth Muscle Cell Phenotypic ModulationChinyere O Ibikunle, Chenyi Xue, Eunyoung Kim, et al.
Cell Reports|July 16, 2020
Macrophage Exosomes Resolve Atherosclerosis by Regulating Hematopoiesis and Inflammation via MicroRNA CargoLaura Bouchareychas, Phat Duong, Sergio Covarrubias, et al.
Infection and Drug Resistance|January 13, 2025
Comparison of Clinical Characteristics and Mortality Outcome in Critical COVID-19 Patients Infected with Alpha and Omicron VariantsHsin-I Cheng, Ko-Wei Chang, Bing-Chen Wu, et al.
Thoracic Cancer|October 16, 2019
Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression controlShih-Hao Huang, Allen Chung-Cheng Huang, Chin-Chou Wang, et al.
Medrxiv : the Preprint Server for Health Sciences|July 28, 2023
High-Dimensional Single-Cell Multimodal Landscape of Human Carotid AtherosclerosisAlexander C Bashore, Hanying Yan, Chenyi Xue, et al.
Frontiers in Oncology|October 19, 2023
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitorsPing-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, et al.
Therapeutic Advances in Medical Oncology|August 11, 2021
First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancerAllen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, et al.
Cancers|January 21, 2022
Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor MutationChih-Hsi Scott Kuo, Tzu-Hsuan Chiu, Pi-Hung Tung, et al.
Scientific Reports|March 16, 2022
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasisTzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, et al.
Targeted Oncology|February 22, 2023
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in TaiwanPing-Chih Hsu, Suey-Haur Lee, Li-Chung Chiu, et al.
Pageof 4